Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Invested Capital (2016 - 2025)

Syndax Pharmaceuticals has reported Invested Capital over the past 11 years, most recently at $64.6 million for Q4 2025.

  • Quarterly results put Invested Capital at $64.6 million for Q4 2025, down 78.47% from a year ago — trailing twelve months through Dec 2025 was $64.6 million (down 78.47% YoY), and the annual figure for FY2025 was $64.6 million, down 78.47%.
  • Invested Capital for Q4 2025 was $64.6 million at Syndax Pharmaceuticals, down from $115.4 million in the prior quarter.
  • Over the last five years, Invested Capital for SNDX hit a ceiling of $554.2 million in Q4 2023 and a floor of $64.6 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $362.8 million (2023), compared with a mean of $325.9 million.
  • Biggest five-year swings in Invested Capital: skyrocketed 216.75% in 2021 and later crashed 78.47% in 2025.
  • Syndax Pharmaceuticals' Invested Capital stood at $408.6 million in 2021, then rose by 14.42% to $467.4 million in 2022, then increased by 18.56% to $554.2 million in 2023, then tumbled by 45.82% to $300.2 million in 2024, then crashed by 78.47% to $64.6 million in 2025.
  • The last three reported values for Invested Capital were $64.6 million (Q4 2025), $115.4 million (Q3 2025), and $157.4 million (Q2 2025) per Business Quant data.